Skip to content
ChickenStockChickenStock
Research377740
BioNote logo

BioNote (377740) stock

KOSPI · Health Care Equipment & Supplies

KRW 4,475-1.00%(-45)

As of Nov 16, 12:02 PM KST

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-2.18x

Net loss — not comparable

P/B

0.29x

P/S

3.53x

Earnings

Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.

Quarters and year-to-date
PeriodRevenueOperating profitNet incomeRevenue YoY
Q2 2026Consolidated · Filed Aug 13, 2026KRW 36.4 billionKRW 8.5 billionKRW 9.1 billion+12.2%
Q1 2026Consolidated · Filed May 14, 2026KRW 32.6 billionKRW 6.3 billionKRW 41.3 billion+14.5%
Q4 2025Consolidated · Filed Mar 18, 2026KRW 28 billionKRW 800 million-KRW 194 billion—
Q3 2025Consolidated · Filed Nov 14, 2025KRW 29.5 billionKRW 4.8 billionKRW 17.9 billion+11.5%
Q2 2025Consolidated · Filed Aug 14, 2025KRW 32.4 billionKRW 6.3 billionKRW 84.5 billion+23.3%
Q1 2025Consolidated · Filed May 15, 2025KRW 28.4 billionKRW 4.7 billionKRW 4 billion+12.4%
Fiscal years
PeriodRevenueOperating profitNet incomeRevenue YoY
FY2025Consolidated · Filed Mar 18, 2026KRW 118.3 billionKRW 16.7 billion-KRW 87.5 billion+15.1%
FY2024Consolidated · Filed Mar 18, 2025KRW 102.8 billionKRW 12.2 billionKRW 55.3 billion—
  • Q2 2026 is computed as H1 2026 minus Q1 2026.
  • Q4 2025 is computed as FY2025 minus 9M 2025.
  • Q3 2025 is computed as 9M 2025 minus H1 2025.
  • Q2 2025 is computed as H1 2025 minus Q1 2025.
Original filing (DART)

Short selling and securities lending

Short sales as a share of trading value, the reported short position and the securities lending balance.

Short-sale share
2.07%
Of trading value on Nov 13, 2026
Short-sale value
KRW 10 million
Previous 20-day average 2.04%
Net short position
0 shares
As of Nov 11, 2026 · reported with a two-trading-day lag
Lending balance
356,080 shares
As of Nov 13, 2026 · 0.35% of listed shares
Recent short-sale days
DateShareValue
Nov 13, 20262.07%KRW 10 million
Nov 12, 20262.67%KRW 10 million
Nov 11, 20262.29%KRW 10 million
Nov 10, 20262.01%KRW 10 million
Nov 9, 20260.34%KRW 0
Nov 6, 20260.20%KRW 0
Nov 5, 20260.19%KRW 0
Nov 4, 20261.02%KRW 0
Nov 3, 20262.10%KRW 10 million
Nov 2, 20260.90%KRW 0

The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.

BioNote (377740) stock information

KOSPI

BioNote (377740) is listed on KOSPI. Its market capitalization is about KRW 455.9 billion. On trailing-twelve-month earnings the P/E ratio is -2.18, and the P/B ratio is 0.29. Return on equity is -13.5%. These figures are computed in-house from official filings and are reference information only.

BioNote — frequently asked questions

What is the P/E ratio of BioNote (377740)?
On a trailing-twelve-month basis, 377740 trades at a P/E ratio of -2.18. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of BioNote?
377740 has a market capitalization of about KRW 455.9 billion. The figure moves with the share price and is refreshed each trading day.
Does BioNote pay a dividend?
377740 has a dividend yield of about 5.09%, based on disclosed payment history. Dividend policy can change; this is reference information only.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.